A method for evaluating an effect of a substance when applied to mammalian skin is provided. The method comprises the steps of: (i) assessing an immune response of the skin of at least one mammal to an antigen, to which the mammal has been sensitized, in order to obtain data; (ii) applying the substance to the skin; (iii) assessing the immune response of the skin to the antigen following the application of the substance to the skin to obtain further data; and (iv) using the data obtained in step...

A method for reducing or maintaining the level of adipose tissue formation in a mammal includes the step of administering a pantethine composition to the mammal in an amount and for a period of time sufficient to achieve a desired body weight. Compositions useful in carrying out the method include an adipose modulating amount of the pantethine component and a pharmaceutically acceptable carrier.

The present invention relates to a therapeutic composition to protect a mammal from B. henselae infection that includes an isolated B. henselae antigen and an adjuvant comprising a phosphazene polymer. Also included is a method to use such a therapeutic composition to protect a mammal from B. henselae infection. One embodiment is a method to protect a human from cat scratch disease by administering such a therapeutic composition to a domestic cat in contact with the human. The present invention ...

The present invention relates to a novel method for testing the developmental status in pancreatic cells of a mammal. The present invention further relates to applications in the medical field that directly arise from the method of the invention. Additionally, the present invention relates to transgenic mammals comprising at least one inactivated Pax4 allele and optionally at least one inactivated Pax6 allele.

Methods and compositions for detecting and localizing light originating from a mammal are disclosed. Also disclosed are methods for tracking light emission to selected regions, as well as for tracking entities within the mammal. In addition, animal models for disease states are disclosed, as are methods for localizing and tracking the progression of disease or a pathogen within the animal, and for screening putative therapeutic compounds effective to inhibit the disease or pathogen.

Peptides can be produced in and purified from the milk of transgenic animals. The peptides are made as fusion proteins with a suitable fusion partner such as .alpha.-lactalbumin, which is a natural milk protein. The fusion partner protein acts to promote secretion of the peptides and, at least in the case of .alpha.-lactalbumin, allows a single-step purification based on specific affinity. The peptide is released from the purified fusion protein by a simple cleavage step and purified away from t...

A preparation and method for increasing cartilaginous mass of joints in a mammal, especially an athlete practicing a sport, are disclosed. The preparation is administered orally on a daily basis and includes hydrolyzed gelatin having a mean molecular weight of from 10,000 to 50,000 Daltons. The preparation also includes a magnesium-containing organic or inorganic compound and B-group vitamins. A daily dose of the preparation contains from 0.01 g to 2 g of the hydrolyzed gelatin, from 0.002 mg to...

Peptides can be produced in and purified from the milk of transgenic animals. The peptides are made as fusion proteins with a suitable fusion partner such as .alpha.-lactalbumin, which is a natural milk protein. The fusion partner protein acts to promote secretion of the peptides and, at least in the case of .alpha.-lactalbumin, allows a single-step purification based on specific affinity. The peptide is released from the purified fusion protein by a simple cleavage step and purified away from t...

A method for determining the immunocompetence of a mammal is described. Bodily fluid having T cell receptor complexes from a mammal is provided. Expression of a first component and a second component of the T cell receptor complexes is evaluated. An abnormal ratio of the number of cells expressing the first component as compared to the number of cells expressing the second component indicates altered immunocompetence in the mammal. Also described are methods for monitoring a therapeutic treatmen...

A method is provided for treating a mammal infected with respiratory syncytial virus (RSV) comprising administering to the mammal an RSV inhibitory effective amount of a compound or its pharmaceutically acceptable salt of the formula ##STR1## wherein R.sup.1 is alkyl, aralkyl, aroyl or acyl and R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are H or acyl.